DOI:
10.1055/s-00000002
Aktuelle Dermatologie
LinksClose Window
References
Pardanani A, Tefferi A, Jamieson C. et al.
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.
Blood Cancer J 2015;
5: e335
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.